Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Sibling Allogeneic Transplantation for Relapsed Hodgkin Lymphoma
2008-004955-31Phase 2Terminated
- Sponsor
- University College London
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, melphalan and alemtuzumab in Hodgkin lymphoma (HL), sponsored by University College London. Primary endpoint: 3-year progression-free survival. Started Jun 2009; status: terminated.
02
Drugs
fludarabinemelphalanalemtuzumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2008-004955-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004955-31.